2030 tashi nung India nung Type-2 diabetes agi shiranger mn 98 ajungtsü

New Delhi/New York, Yimpoksüi/November 21 (Agencies): 2018 küm alima nung Type-2 diabetes agi shiranger million 406 lir, aser 2030 küm nungbo iba tashidak agi shiranger million 511 ajungtsü; high blood sugar agi shiranger tesadang kabo India aser China nungi asütsü, ta India nunger research agir kati asadangtetogo.
Iba study ya Lancet Diabetes and Endocrinology journal nung sangdonga liasü.
Iba study ajanga bushitetba agi, 2030 küm tashi nung Type-2 diabetes agi shiranger China nunger million 130 alitsü, India nunger million 98 alitsü, iba sülen US nunger million 32 alitsü, aser ibaji alima nung iba tashidak agi shiranger tesadang ka shi asütsü.
Ibaji ajanga taruba küm 12 nung alima nung Type-2 diabetes atema mozü-insulin shilem 20 dak tema nüngdaktsü.
“UN-i memenatepba tashidak balala atema treatment agutsütsü aser ajak nem diabetes mozü agutsütsü atema inyaker, ajisüaka alima nung insulin agi anünger aser shirangertemi kanga saaka angur,” ta Stanford University, US nungi Sanjay Basu-i metetdaktsü.
“Taruba küm 12 nung taintem Type-2 diabetes agi kanga bulua shirangtsü aser ibaji tain akumba, yimtitemi oa litepba, chia-jemba yimba aser physical activity kulitem ajanga lir,” ta paisa ashi.
Iba study agidang team-i International Diabetes Federation indang data 14 amshiba den külemi cohort study 14 agi, iba denji külemi linük 221 nung Type-2 diabetes agi shirangba asadanga liasü.
Alima nung Type-2 diabetes agi kanga bulua shirangteper, aser iba atemaji insulin mozü nüngdaktsü, ajisüaka insulin treatment agitsüji jenjang kanga tasak aser international insulin market ji manufacturers asemi dang agia lir, ta research agirtemisa metetdaktsü.